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Risk gene variantsBackground: Diabetes mellitus is considered a major public health problem worldwide. Susceptibility to
diabetes is influenced by both genetic and environmental determinants.
Aims/hypothesis: The aim of the present study was to test for 16 independent single nucleotide polymor-
phisms (SNPs) in established Type 2 diabetes (T2D) and obesity susceptibility loci by GWAS in a sample of
Egyptian patients to find out if there is shared genetic background underlying both disease entities.
Methods: Genotyping was performed using OpenArray protocol on the QuantStudioTM 12K Flex Real-
Time PCR System. In the present case control study a custom array was designed to facilitate cost-
effective analysis of selected SNPs related to glycolysis, gluconeogenesis, inflammation, insulin signalling,
and immune function.
Results: Seven gene variants showed significant association with the risk of T2D patients including
FCGRA2, STAT4, CELSR2, PPARG, EXT2 rs3740878, GCKR, PTGS1. Factors that significantly affect T2D were
obesity (p < 0.001) and GCKR (p = 0.001) and PTGS1 (p = 0.001) gene variants. Gene variants that showed
significant or borderline effect on obesity were MTHFD1, EXT2 rs3740878, GCKR and PTGS1 (p = 0.03,
0.017, 0.059, 0.006) respectively.
Conclusions/interpretation: Overlapping genetic aspects should be considered and the presence of risk
alleles of different genes together could contribute to the risk of T2D or obesity or both. The MTHFD1
and EXT2rs3740878 gene variants significantly affect obesity and not shared with T2D. Gene variants that
showed combined effect on both disease entities were GCKR and PTGS1. These findings provide a basis for
future studies on a larger scale. More stress on the risk gene variants that have a combined impact on
both diabetes and obesity is recommended to improve risk prediction and preventive strategies.
 2017 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is considered a major public health problem
worldwide. In 2015 the International Diabetes Federation indi-
cated that 415 million adults live with diabetes mellitus in the
world. In Egypt over 7.8 million adult cases were reported with
14.9% prevalence [1]. Susceptibility to diabetes is influenced by
both genetic and environmental determinants. The major environ-
mental risk factors for Type 2 diabetes (T2D) are obesity and a
sedentary lifestyle. Waist-to-hip circumference ratio (WHR), corre-
sponding to fat distribution also has an impact on T2D risk [2,3].Additionally, chronic inflammation or infections might provoke
insulin resistance and thereby contribute to the development of
diabetes and its complications [4].
Advances in genotyping technology during the last years have
facilitated rapid progress in large-scale genetic studies The large
scale genome wide association studies (GWAS) have identified
approximately 80 single nucleotide polymorphisms (SNPs) confer-
ring susceptibility to type 2 diabetes (T2D) [5].
The OpenArray, a new platform technology on the QuantStu-
dioTM 12K Flex Real-Time PCR System accelerates genomic confir-
mation and screening, enabling unprecedented gene coverage
and sample throughput [6]. In the present study a custom array
was designed to facilitate cost-effective analysis of independent
single nucleotide polymorphisms (SNPs) related to glycolysis, glu-
coneogenesis, inflammation, insulin signalling, and immune func-
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apeutic strategies. The common variant associated with T2D,
PPARG, is a well-established target of thiazolidinedione (TZD)
drugs, and used clinically to reduce insulin resistance in T2D
patients [7].
Sixteen SNPs at established T2D and obesity susceptibility loci
by GWAS were tested using new OpenArray genotyping protocol
among Egyptian patients. Association between genetic variants
and the risk of T2D and obesity was analysed to find out if there
is shared genetic background underlying both disease entities.2. Subjects and methods
A case - control study of 74 Egyptian participants; 37 patients
with type 2 diabetes mellitus (T2D) (mean age: 48.6 ± 9.7 years;
M/F: 16/21) and 37 non-diabetics age and sex matched (mean
age: 45.4 ± 10.2 years; M/F: 15/22) were investigated. Sample size
has been adjusted to the used Open Array platform. Diabetic
patients were recruited from Ein-Shams University and National
Institute of Diabetes and Endocrinology in 2014–2015. All labora-
tory investigations and genetic studies were performed at the
Medical Molecular Laboratory Research Unit at National Research
Centre, Clinical and Chemical Pathology department. This work
has been carried out in accordance with the Code of Ethics of the
World Medical Association (Declaration of Helsinki) for experi-
ments in humans and was approved by the ethical committee of
the National Research Centre. All patients and controls provided
informed consent for their participation in the study. Patients were
subjected to medical history with special emphasis on demo-
graphic and related clinical data, age of onset of T2D, family his-
tory, history of drug intake and type of treatment for diabetes.
Patients with T2D were diagnosed according to American Diabetes
Association guidelines [8].
Body weight (WT), height (HT), waist circumference (WC), and
hip circumference (HC) were measured using standard methods,
and body mass index (BMI) was calculated as weight/height2 (kg/
m2) for all participants. All participants were then classified
according to BMI into two groups; diabetic obese patients




Patients who receive treatment for inflammatory or chronic
infectious disease or malignancy were excluded from the study.
2.2. Blood Chemical analyses
Venous blood samples were obtained from all participants for
measuring fasting plasma glucose (FPG), fasting insulin (F Ins),
and glycosylated haemoglobin (HbA1c) using standard biochemi-
cal analysis. The homeostasis model assessment for beta cell func-
tion (HOMA-B) and the homeostasis model assessment for insulin
resistance (HOMA-IR) were used to assess insulin resistance. The
formulas were as follows:
HOMA-B = Fasting serum insulin  20/(FPG  3.5) (with serum
insulin in mU/l and plasma glucose in mmol/l).
HOMA-IR = fasting serum insulin  FPG/22.5.
2.3. Genetic analyses
All participants were genotyped for: Methylenetetrahydrofolate
dehydrogenase 1 (MTHFD1) (rs2236225); Fc fragment of IgG, low
affinity 2A (FCGR2A) (rs1801274); signal transducer and activatorof transcription 4 (STAT4) (rs7574865); complement factor B
(CFB) (rs547154); Cadherin, EGF LAG Seven-Pass G-Type Receptor
2 (CELSR2) (rs599839); fat mass and obesity-associated gene
(FTO) (rs17817449); rs10811661 upstream of cyclin-dependent
kinase inhibitor 2A/B (CDKN2A/B); hemochromatosis gene (HFE)
(rs1800562); peroxisome proliferator-activated receptor-gamma
(PPARG) (rs1801282); neuropeptide Y (NPY) (rs16147); exostosin-
2 (EXT2) (rs11037909, rs3740878); glucokinase (hexokinase 4) reg-
ulator (GCKR) (rs780094); C-reactive protein (CRP) (rs2808630);
prostaglandin-endoperoxide synthase 1 (PTGS1) (rs5788); the
intergenic variant of chromosome 11p12 (rs9300039).
Custom array with TaqMan assays were designed by the Bioin-
formatics Group at Life Technologies to facilitate cost-effective
genotyping using QuantStudioTM 12K Flex OpenArray genotyping
protocol (Custom TaqMan SNP Genotyping kit including plates
and accessories). Selected format of OpenArrayTM Plates allowed
the performance of the required 16 assays for all the samples.
2.3.1. Preparing the DNA samples
Five milliliters of whole blood were collected from each subject
into tubes containing ethylene-diamine-tetra-acetic acid (EDTA).
Genomic DNA (gDNA) was purified using the QIAcube automated
instrument according to the manufacturer’s guidelines (Qiagen,
Germany). DNA quality and quantity were adjusted at A260/280
ratio between 1.7 and 1.9 by NanoDrop ND-1000 (PeqLab) and nor-
malized to the recommended working concentration at 50 ng/lL.
The gDNA samples were stored at 80 C until further use. The
TaqMan PCR reaction was performed using TaqMan OpenArrayTM
Master Mix (Life Technologies) according to the manufacturer’s
recommendation.
2.3.2. Setting up the 96 well plates [9]
The concentration of the thawed normalized genomic DNA
samples was reviewed. 5.0 microliter (lL) of the DNA samples
was put into the appropriate number of wells of a 96‐well Micro-
Amp Optical Reaction Plate according to the selected format of
OpenArrayTM Plates. Then Tracking the samples from the 96 well
plate to the TaqMan OpenArrayTM 384-Well sample plate was per-
formed using sample tracker software provided by the equipment.
2.5 lL of master mix and 2.5 ll of normalized DNA samples were
added to the 384‐well sample plate. Then the QuantStudio OpenAr-
ray AccuFill Software was initialized for loading onto the OpenAr-
rayTM plates. Then the plate was immediately sealed and immersion
fluid was injected. At this step the sealed OpenArray plate is ready
to be loaded into the QuantStudio 12K Flex System and thermal
cycling was performed according to the manufacturer’s recom-
mendation. Analysis of the genotyping results was performed
using provided TaqMan Genotyper software.
2.4. Statistical methods
All test data were converted and manipulated by using SPSS
software program version 18.0. Data were analysed, mean and
standard deviation were calculated as regards quantitative demo-
graphic, anthropometric and biochemical data. The quantitative
data were compared and t test was applied and p value was estab-
lished to determine the statistically significant difference between
two groups. While numbers and percent were calculated and pre-
sented among groups as regards qualitative data. To determine the
relationship strength between variables statistical correlation
study was performed and coefficient of correlation (r) was mea-
sured. Allelic discrimination was analysed using Hardy–Weinberg
equilibrium (HWE) analysis tool supplied with the Taqman Geno-
typer software on the QuantStudioTM 12K Flex Real-time PCR sys-
tem. Chi-square test was used for testing the association of gene
variants with disease entities and for estimating the odds ratios
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was applied to determine the linear relationship between a depen-
dent variable and a series of independent variables. Multiple logis-
tic regression was used when studying the effect of
one nominal and two or more measurement variables. The differ-
ence between the two groups was considered statistically signifi-
cant when p < 0.05, and considered highly statistical significant
when p < 0.01.3. Results
The demographics, anthropometric and biochemical findings of
the participants are listed in Table 1. Diabetes duration ranged
from 0.2 to 22 years. Of diabetic patients 86.5% have positive fam-
ily history. Of female subjects 44.2% and of male subjects 25.8%
were obese with BMI  30. Of diabetic patients 70.3% were on
insulin therapy and 29.7% were on hypoglycemic drugs. Anthropo-
metric indices [WT, WC, HC, and waist to hip ratio (WHR)] were
significantly increased in diabetic patients when compared to
non-diabetic participants with p < 0.001. Mean levels of FPG,
HbA1c were significantly higher in diabetic patients in comparison
to the non-diabetic participants. Highly significant reduction of
HOMA-B in the T2D patients was detected compared to non-
diabetic participants.
WHR showed highly significant positive correlation with BMI,
FPG, HbA1c and HOMA-IR (r = 0.375 and p < 0.001, r = 0.269 and
p = 0.001; r = 0.430 and p < 0.001; r = 0.234 and p = 0.004 respec-
tively). Also, BMI showed highly significant positive correlation
with FPG (r = 0.493), HbA1c (r = 0.606) with p < 0.001. Highly sig-
nificant negative correlation was detected between BMI and
HOMA-B (r = 0.416 and p = <0.001) and borderline significance
between WHR and HOMA-B (r = 0.161 and p = 0.051).
Significantly increased BMI was observed in association with
risk variants of MTHFD1 (p = 0.016), STAT4 (p = 0.014), PPARG
(p = 0.001), EXT2 rs3740878 (p < 0.001), GCKR (p = 0.004), PTGS1
(p = 0.004) and borderline significance with FTO variant (p = 0.07).
To determine the influence of obesity cofactor in the genetic
variation analyses we compared obese diabetic patients (N = 26
and BMI> = 30) with non-obese non-diabetic control individualsTable 1
Demographic, biochemical and anthropometric characters of studied subjects.
Variables Diabetic patients (n = 37)
Age Years 48.7 ± 9.8
Sex no (%) Female 21 (56.8)
Male 16 (43.2)
Weight kg 84.9 ± 10.7
Height cm 163.1 ± 9.6
BMI kg/m2 32.5 ± 4.4
WC cm 106.9 ± 11.7
HC cm 114.0 ± 10.2
WHR 0.938 ± .05
FPG mg/dl (mmol/l) 199.1 ± 66.2 (11.06 ± 3.67
HBA1C % (mmol/mol) 8.7 ± 2.1 (72.6 ± 22.9)
F Ins mU/l 11.5 ± 14.9
HOMA B Median (IQR) 16.3 (4.9–59.6)
HOMA IR 5.3 ± 3.6
Type of treatment No (%)
Insulin 26 (70.3)
Oral 11 (29.7)
F history No (%)
Yes 32 (86.5)
No 5 (13.5)
DD Years (range) 8.4 ± 7.1 (0.2–22)
BMI: body mass index, Waist circumference: WC, Hip circumference: HC, WHR: waist-to-
F history: Family history, DD: Duration of disease.
a Statistical significant difference p < 0.05.
b Statistical highly significant difference p < 0.01.(N = 36). Genotype frequencies in all the studied groups are
demonstrated in Table 2.
The magnitude of risk (OR) of the different risk alleles for all
diabetic and obese-diabetic patients are presented in Table 3. Of
all tested genetic variants seven SNPs showed significant associa-
tion with the risk of T2D including FCGR2A, STAT4, CELSR2, PPARG,
EXT2 rs3740878, GCKR, PTGS1. Eight SNPs showed significant
association with the risk of obesity with T2D including MTHFD1,
STAT4, CELSR2, FTO, PPARG, EXT2 rs3740878, GCKR, PTGS1.
Significant associations between risk alleles of PPARG, EXT2
rs3740878, GCKR, PTGS1 gene variants and increased FPG levels
were observed (p = 0.001, <0.001, 0.002, 0.001 respectively). Risk
alleles of STAT4, PPARG, EXT2 rs3740878, GCKR, PTGS1 gene variants
showed significant associations with increased HbA1c levels
(p = 0.034, 0.004, 0.003, <0.001, 0.003 respectively) and decreased
HOMA-B (p < 0.001, 0.016, 0.001, 0.046, 0.003 respectively). The
only significant association with increased HOMA-IR was observed
with the risk allele of STAT4 gene variant (p = 0.008). Also STAT4
and EXT2 rs3740878 risk alleles were significantly associated with
reduced F Ins levels (p = <0.001 and 0.03 respectively).
With logistic regression analysis we found that factors that sig-
nificantly affect T2D were obesity and GCKR and PTGS1 gene vari-
ants (p < 0.001, 0.001, 0.001) respectively (Table 4).
On the other hand gene variants that showed significant or bor-
derline impact on obesity were MTHFD1, EXT2 rs3740878, GCKR
and PTGS1 (p = 0.03, 0.017, 0.059, 0.006) respectively (Table 5).
These findings clarified that the gene variants that significantly
affect obesity and not shared with T2D were the MTHFD1 and
EXT2 rs3740878 gene variants. GCKR and PTGS1 gene variants
showed combined effect on both disease entities.4. Discussion
In the present study we used a new platform technology on the
QuantStudioTM 12K Flex Real-Time PCR System. Custom array was
designed to perform genotyping of all selected independent
genetic variants in Egyptian patients with T2D with and without
obesity. Both T2D and obesity are associated frequently and con-
sidered as key components of metabolic syndrome [10]. In thisMean ± SD Control subjects (n = 37) Mean ± SD p
45.5 ± 10.3 0.176
22 (59.5) 0.814
15 (40.5)
72.8 ± 9.0 <0.001b
168.5 ± 9.3 0.017a
24.9 ± 2.2 <0.001b
78.7 ± 9.7 <0.001b
88.8 ± 9.6 <0.001b
0.886 ± .03 <0.001b
) 87.5 ± 12.6 (4.86 ± 0.7) <0.001 b
5.1 ± 0.7 (31.1 ± 6.1) <0.001b
16.5 ± 9.6 0.087
223.0 (112.3–500.0) <0.001b




hip ratio, FPG: Fasting plasma glucose, F Ins: Fasting insulin, IQR: interquartile range,
Table 2
Genotype frequencies among all the studied groups.
















N = 26 n (%)
Non-obese
non-diabetic




MTHFD1 Rs2236225 14:64442127 G/A AA 31 (83.8) 34 (91.9) 1.138 0.286 20 (76.9) 34 (94.4) 4.124 0.042a
AG 6 (16.2) 3 (8.1) 6 (23.1) 2 (5.6)
FCGR2A Rs1801274 1:161509955 G/A GG 4 (10.8) 0 4.515 0.105 3 (11.5) 0 4.373 0.112
AG 6 (16.2) 5 (13.5) 3 (11.5) 5 (13.9)
AA 27 (73.0) 32 (86.5) 20 (76.9) 31 (86.1)
STAT4 Rs7574865 2:191099907 T/G TT 26 (70.3) 19 (51.4) 5.446 0.066 20 (76.9) 18 (50.0) 6.666 0.036a
GT 5 (13.5) 3 (8.1) 3 (11.5) 3 (8.3)
GG 6 (16.2) 15 (40.5) 3 (11.5) 15 (41.7)
CFB Rs547154 6:31943161 T/G TT 14 (37.8) 13 (35.1) 1.791 0.408 10 (38.5) 12 (33.3) 1.816 0.403
GT 14 (37.8) 10 (27.1) 10 (38.5) 10 (27.8)
GG 9 (24.3) 14 (37.8) 6 (23.1) 14 (38.9)
CELSR2 Rs599839 1:109279544 A/G AA 5 (13.5) 0.0 6.815 0.033a 3 (11.5) 0.0 5.873 0.05a
AG 14 (37.8) 11 (29.7) 10 (38.5) 10 (27.8)
GG 18 (48.6) 26 (70.3) 13 (50.0) 26 (72.2)
FTO Rs17817449 16:53779455 T/G GG 17 (45.9) 23 (62.2) 3.4 0.183 10 (38.5) 23 (63.9) 5.693 0.058
GT 18 (48.6) 14 (37.8) 14 (53.8) 13 (36.1)
TT 2 (5.4) 0 2 (7.7) 0
CDKN2A/B Rs10811661 9:22134095 T/C TT 7 (18.9) 0 8.913 0.012a 6 (23.1) 0 10.371 0.006
bCT 13 (35.1) 21 (56.8) 8 (30.8) 20 (55.6)
CC 17 (45.9) 16 (43.2) 12 (46.2) 16 (44.4)
HFE Rs1800562 6:26092913 A/G AA 13 (35.1) 13 (35.1) 6.454 0.04 a 9 (34.6) 12 (33.3) 3.516 0.172
AG 21 (56.8) 13 (35.1) 14 (53.8) 13 (36.1)
GG 3 (8.1) 11 (29.7) 3 (11.5) 11 (30.6)
PPARG Rs1801282 3:12351626 G/C GG 14 (37.8) 5 (13.5) 12.111 0.002b 10 (38.5) 5 (13.9) 9.243 0.01a
CG 18 (48.6) 14 (37.8) 12 (46.2) 13 (36.1)
CC 5 (13.5) 18 (48.6) 4 (15.4) 18 (50.0)
NPY Rs16147 7:24283791 C/T CC 24 (64.9) 25 (67.6) 0.06 0.806 16 (61.5) 24 (66.7) 0.173 0.677
CT 13 (35.1) 12 (32.4) 10 (38.5) 12 (33.3)
EXT2 Rs11037909 11:44234064 T/C TT 16 (43.2) 14 (37.8) 1.162 0.559 13 (50.0) 13 (36.1) 1.234 0.54
CT 18 (48.6) 17 (45.9) 10 (38.5) 17 (47.2)
CC 3 (8.1) 6 (16.2) 3 (11.5) 6 (16.7)
EXT2 Rs3740878 11:44236252 T/C TT 4 (10.8) 0 9.165 0.01a 4 (15.4) 0 9.755 0.008b
CT 12 (32.4) 5 (13.5) 8 (30.8) 5 (13.9)
CC 21 (56.8) 32 (86.5) 14 (53.8) 31 (86.1)
GCKR Rs780094 2:27518370 T/C TT 11 (29.7) 0 14.457 0.001b 6 (23.1) 0 11.37 0.003b
CT 14 (37.8) 14 (37.8) 12 (46.2) 14 (38.9)
CC 12 (32.4) 23 (60.0) 8 (30.8) 22 (61.1)
CRP Rs2808630 1:159711078 T/C TT 18 (48.6) 22 (59.5) 2.3 0.317 15 (57.7) 22 (61.1) 1.024 0.599
CT 15 (40.5) 9 (24.3) 9 (34.6) 9 (25.0)
CC 4 (10.8) 6 (16.2) 2 (7.7) 5 (13.9)
PTGS1 Rs5788 9:122381513 A/C AA 6 (16.2) 0 11.937 0.003b 3 (11.5) 0 7.854 0.02a
AC 17 (45.9) 10 (27.0) 12 (46.2) 10 (27.8)
CC 14 (37.8) 27 (73.0) 11 (42.3) 26 (72.2)
Intergenic Rs9300039 11:41893816 C/T CC 15 (40.5) 20 (54.1) 1.982 0.371 10 (38.5) 19 (52.8) 1.358 0.507
CT 19 (51.4) 13 (35.1) 13 (50.0) 13 (36.1)
TT 3 (8.1) 4 (10.8) 3 (11.5) 4 (11.1)
a Statistical significant difference p < 0.05.
b Statistical highly significant difference p < 0.01.
c BMI  30.
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ground underlying these diseases in a sample of Egyptian patients.
Many previous studies have shown that obesity is associated
with increased risk of diabetes [11–13]. In the current work corre-
lation studies revealed significant positive correlation between
BMI and central fat accumulation (WHR), and FPG and HbA1c
blood levels. Inverse association was detected between BMI and
beta cell function (HOMA-B). Also logistic regression analysis
demonstrated that obesity is the most significant factor affecting
T2D. These findings suggested that management of BMI could sig-
nificantly improve beta cell function and reduce the risk of T2D.
Of all tested genetic risk variants seven SNPs showed significant
association with the risk of T2D including FCGRA2, STAT4, CELSR2,
PPARG, EXT2 rs3740878, GCKR and PTGS1. On the other hand eight
SNPs showed significant association with the risk of obesity with
T2D including MTHFD1, STAT4, CELSR2, FTO, PPARG, EXT2
rs3740878, GCKR and PTGS1.4.1. FCGRA2, STAT4 and HFE
To the best of our knowledge, the FCGR2A association with T2D
has not been previously investigated. FCGR2A is a member of a
family of immunoglobulin Fc receptor genes found on the surface
of many immune-response cells. In the current study FCGR2A risk
allele showed significant association with risk of T2D. This finding
raises the possibility of inflammatory pathogenic mechanism as a
risk factor for T2D.
STAT4 is a central inflammatory mediator that is s required for
the development of fully functional T helper1 cells. In the present
work STAT4 risk allele showed significant association with the risk
of both T2D and obesity. A previous study by Yang et al. suggested
that clinical insulin-dependent diabetes mellitus could be pre-
vented in prediabetic individuals at risk through selective inhibi-
tion of the STAT4 activation pathway [14]. A meta-analysis
investigated the STAT4 polymorphisms and diabetes risk found
Table 3
Risk allele frequencies among all the studied groups.




N = 37 %
Control
N = 37 %
Odds ratio
(95% CI)
P value Diabetic – obese
patientsc N = 26 %
Non-obese
non-diabetic




MTHFD1 Rs2236225 G 8.1 4.1 2.1 (0.5–8.9) 0.302 11.5 2.8 4.6 (0.9–23.6) 0.05a
A 91.9 95.9 88.5 97.2
FCGR2A Rs1801274 G 18.9 6.8 3.2 (1.1–9.5) 0.027a 17.3 6.9 2.8 (0.9–8.9) 0.072
A 81.1 93.2 82.7 93.1
STAT4 Rs7574865 T 77.0 55.4 2.7 (1.3–5.5) 0.005b 82.7 54.2 4.0 (1.7–9.5) 0.001b
G 23.0 44.6 17.3 45.8
CFB Rs547154 T 56.8 48.6 1.4 (0.7–2.6) 0.324 57.7 47.2 1.5 (0.7–3.1) 0.25
G 43.2 51.4 42.3 52.8
CELSR2 Rs599839 A 32.4 14.9 2.7 (1.2–6.1) 0.012a 30.8 13.9 2.8 (1.1–6.7) 0.023a
G 67.6 85.1 69.2 86.1
FTO Rs17817449 T 29.7 18.9 1.8 (0.8–3.9) 0.125 34.6 18.1 2.4 (1.0–5.5) 0.036a
G 70.3 81.1 65.4 81.9
CDKN2A/B Rs10811661 T 36.5 28.4 1.4 (0.7–2.9) 0.293 38.5 27.8 1.6 (0.8–3.5) 0.209
C 63.5 71.6 61.5 72.2
HFE Rs1800562 A 63.5 52.7 1.6 (0.8–3.0) 0.184 61.5 51.4 1.5 (0.7–3.1) 0.262
G 36.5 47.3 38.5 48.6
PPARG Rs1801282 G 62.2 32.4 3.4 (1.7–6.7) <0.001b 61.5 31.9 3.4 (1.6–7.2) 0.001b
C 37.8 67.6 38.5 68.1
NPY Rs16147 C 82.4 83.8 0.9 (0.4–2.1) 0.826 80.8 83.3 0.8 (0.3–2.1) 0.712
T 17.6 16.2 19.2 16.7
EXT2 Rs11037909 T 67.6 60.8 1.3 (0.7–2.6) 0.392 69.2 59.7 1.5 (0.7–3.2) 0.277
C 32.4 39.2 30.8 40.3
EXT2 Rs3740878 T 27.0 6.8 5.1 (1.8–14.5) 0.002b 30.8 6.9 6.0 (2.0–17.6) <0.001b
C 73.0 93.2 69.2 93.1
GCKR Rs780094 T 48.6 18.9 4.1 (1.9–8.5) <0.001b 46.2 19.4 3.6 (1.6–7.9) 0.001b
C 51.4 81.1 53.8 80.6
CRP Rs2808630 T 68.9 71.6 0.8 (0.4–1.8) 0.719 75.0 73.6 1.1 (0.5–2.4) 0.862
C 31.1 28.4 25.0 26.4
PTGS1 Rs5788 A 39.2 13.5 4.1 (1.8–9.3) <0.001b 34.6 13.9 3.3 (1.4–7.9) 0.006b
C 60.8 86.5 65.4 86.1
Intergenic Rs9300039 C 33.8 28.4 1.3 (0.6–2.6) 0.478 36.5 29.2 1.4 (0.7–3.0) 0.386
T 66.2 71.6 63.5 70.8
a Statistical significant difference p < 0.05.
b Statistical highly significant difference p < 0.01.
c BMI  30.
Table 4
Logistic Regression determining factors affecting diabetes mellitus.
Variable B S.E Wald df Sig Exp(B)
Obesity 5.183 .881 34.613 1 <0.001a 178.172
FCGR2A 1.600 .859 3.464 1 .063 4.951
CDKN2A/B -1.071 .640 2.799 1 .094 .343
GCKR 2.007 .607 10.941 1 0.001 a 7.444
PTGS1 2.174 .639 11.582 1 0.001 a 8.795
Constant -17.346 3.069 31.953 1 .000 .000
Variable(s) entered on step 1: obesity, FCGR2A, STAT4, MTHFD1, CELSR2, FTO, CDKN2A/B, HFE, PPARG, EXT2(rs3740878), GCKR, PTGS1.
a Statistical significant difference p < 0.05.
b Statistical highly significant difference p < 0.01.
Table 5
General Linear Model determining genes affecting BMI.a,b
Variable Type III Sum of Squares Mean Square F Sig.
MTHFD1 96.51 96.51 4.834 0.03a
EXT2 (rs3740878) 116.69 116.69 5.845 0.017a
GCKR 72.79 72.79 3.646 0.059
PTGS1 154.72 154.72 7.749 0.006b
STAT4 * PTGS1 102.63 102.63 5.36 0.022a
Variable(s) entered: FCGR2A, STAT4, MTHFD1, CELSR2, FTO, CDKN2A/B, HFE, PPARG, EXT2(rs3740878), GCKR, PTGS1.
a Statistical significant difference p < 0.05.
b Statistical highly significant difference p < 0.01.
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diabetes risk, especially diabetes type 1. However, they did not give
consistent results for T2D [15]. They postulated the mechanisms by
which chronic inflammation or infections could provoke insulinresistance and thereby contribute to the development of diabetes
and its complications. Macrophages release cytokines that cause
cells of liver and muscle to be insulin resistant. Another mecha-
nism that is more consistent with the current study is to affect
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denced by the highly significant decrease in the fasting insulin
levels and HOMA-B in association with STAT4 gene variant. Also
STAT4 gene was the only variant that showed significant associa-
tion with insulin resistance (HOMA-IR) in the studied patients.
Additionally STAT4 effect on T2D might be mediated by its impact
on obesity. Several mechanisms were proposed to understand the
links between obesity and inflammation. Obesity increases the
severity of pancreatitis through upregulation of the inflammatory
response. Obesity reduces the number of T-regulatory cells and
increases the number of CD8+ T cells, which promotes macrophage
recruitment and increases levels of the proinflammatory hormone
leptin and decreases its anti-inflammatory counterpart, adiponec-
tin [16].
The hemochromatosis gene (HFE) codes for a protein that func-
tions to regulate circulating iron uptake by regulating the interac-
tion of the transferrin receptor with transferrin. This gene has been
suggested to be involved in the etiology of type 2 diabetes mellitus
in previous studies [17,18].
In the present work the AA and AG genotype frequencies were
significantly higher in diabetic patients compared to non-diabetic
participants with p = 0.04. A previous study speculated that the rel-
atively strong association of increased serum ferritin levels with
abnormal glucose tolerance raises the possibility that progressive
iron accumulation in the pancreas contributes to beta cell dysfunc-
tion and abnormal glucose tolerance [18]. In addition the HFE pro-
tein functions to regulate the expression of hepcidin, a secreted
hepatocyte peptide that is the principal regulator of iron home-
ostasis. Hepcidin production increases with iron loading and
inflammation [19]. These findings added evidence for the link
between inflammation and T2D pathogenesis.4.2. PPARG
PPARG gene is a target for the hypoglycemic drugs known as thi-
azolidinediones. PPARG is one of the few genes that have been con-
firmed to be associated with insulin resistance [20]. The PPARG
rs1801282 C > G polymorphism also known as Pro12Ala, a SNP in
exon 2 of PPARG, encodes a proline? alanine substitution at amino
acid residue 12. The more common (C) allele encodes the ’Pro’
amino acid at this SNP position [20,21].
In our results rs1801282 was investigated and PPARG Ala-allele
showed highly significant association with T2D risk (p < 0.001).
The GG genotype frequency was highly significantly increased in
diabetic patients (p = 0.002). The presence of Ala-allele was signif-
icantly related to increased blood levels of FPG and HbA1c and
decreased HOMA-B supporting its impact on glucose metabolism
and beta cell function.
These results are in line with the previous Finnish Diabetes
Prevention Study that investigated 522 subjects with impaired glu-
cose tolerance and subjected them to either placebo or a lifestyle
intervention. They reported a twofold increase in risk of developing
T2D among alanine carriers in the placebo arm when compared to
proline homozygotes P/P [22]. On the other hand, the much larger
Botnia Prospective Study (N = 2293) documented a hazard ratio for
developing diabetes of 1.7 among P/P homozygotes, a result which
was statistically significant [23].
In our results the Ala-allele bearers had a significantly higher
risk of obesity (p = 0.001) and the presence of the gene variant
was significantly associated with increased BMI.4.3. EXT2
Exostosin (EXT) proteins may affect beta-cell mass and insulin
secretion capacity in humans, and render subjects at a higher riskof developing type 2 diabetes when exposed to environmental risk
factors [24,25].
In the current work we studied two SNPs of (EXT2) gene
(rs3740878 and rs11037909). We found an association between
rs3740878 and the risk of T2D which is consistent with previous
studies [26]. The risk allele frequency was highly significantly
increased in diabetic patients compared with non-diabetic individ-
uals. The same was observed when comparing obese diabetic
patients with non-obese non-diabetic individuals. We found a sig-
nificant association between the risk allele of rs3740878 and
increased FPG, HbA1c, F Ins blood levels and BMI and with reduced
HOMA-B. These findings support the impact of this gene variant on
glucose metabolism, beta cell function and obesity. Logistic regres-
sion analysis showed that EXT2 rs3740878 gene variant signifi-
cantly affects obesity only and did not reach significance with
T2D indicating that its role in T2D might be mediated by its asso-
ciation with obesity.
Marginal association for the rs3740878 (OR = 1.07, 95%
CI = 0.99–1.16, p = 0.09) was previously reported in a replication
and meta-analysis [27]. Three single nucleotide polymorphism
(SNP), rs3740878, rs11037909 and rs1113132, in the EXT2 gene
were genotyped in a Chinese case control study and suggested that
the EXT2 gene might not have a major role in the development of
type 2 diabetes in the Chinese population. The same was found
in a Lebanese case control study [28,29]. Gene–environment and
gene-gene interactions should be considered for these discrepan-
cies in literature.4.4. GCKR
The GCKR gene product is a regulatory protein that inhibits glu-
cokinase in liver and pancreatic islet cells by binding non-
covalently to form an inactive complex with the enzyme. In the
current work the GCKR rs780094 risk allele was significantly asso-
ciated with risk of both type 2 diabetes and obesity. The TT and CT
genotypes were significantly more frequent in both disease enti-
ties. The risk variant showed a significant association with
increased FPG and HbA1c blood levels and BMI and reduced
HOMA-B. These are consistent with observations in white Euro-
peans and Han Chinese individuals [30,31]. Conversely Tam et al.
observed significant associations of the minor T-allele of GCKR
rs780094 with decreased FPG (P = 0.013) [32]. Regression analysis
in the present work demonstrated statistical significance with both
T2D and obesity indicating its impact on both disease entities.4.5. CELSR2
The protein encoded by this gene (Cadherin EGF LAG seven-pass
G-type receptor 2) is a member of the flamingo subfamily, part of
the cadherin superfamily. In the current study, the CELSR2 risk
allele frequency was significantly increased in diabetic patients
when compared with non-diabetic individuals. The same was
found when comparing obese diabetic patients with non-obese
non-diabetic individuals. The risk allele showed significant associ-
ation with risk of T2D and obesity. In the present study no impact
of the gene variant could be revealed on both T2D and obesity by
logistic regression analysis and no association could be detected
between CELSR2 risk allele and BMI or glycaemic level. Ahluwalia
et al. identified three loci (CELSR2, HNF1A, and GCKR) significantly
associated with T2D. They stated that the association with the
CELSR2 locus has not been shown previously [33]. Other investiga-
tors previously studied the lipid-metabolizing genetic polymor-
phisms and the BMI. They confirmed their association with
dyslipidemia, however, they did not find association with higher
BMI [34,35]. From these findings the CELSR2 might be associated
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impact on both diseases.4.6. PTGS1
PTGS1/COX-1 gene was selected for genotyping in the present
study based on its role in regulation of angiogenesis in endothelial
cells and inflammatory response. It has been suggested that the
hypercoagulable state in T2D could be as a result of disturbances
of platelet activation, aggregation and lifespan, in addition to the
pro-inflammatory state and endothelial dysfunction [36,37].
Endogenous prostanoids have long been known as inhibitors of
insulin secretion [38]. There is evidence that genetic variants in
the PTGS1 gene alter the metabolism of arachidonic acid to prosta-
glandin H2 and prostaglandin F2, the precursors of prostacyclin,
thromboxane, and several other prostaglandin metabolites [39].
In the present study the PTGS1 risk allele frequency was highly
significantly increased in diabetic patients when compared with
non-diabetic individuals. The same observation was obtained
when comparing obese diabetic patients with non-obese non-
diabetic individuals. The risk allele was significantly associated
with increased FPG, HbA1c blood levels, BMI and decreased
HOMA-B. Regression analysis indicated the effect of this gene vari-
ant on both T2D and obesity that could be related to its impact on
glucose metabolism and obesity resulting in reduced beta cell
function.4.7. FTO
Within the FTO gene, many SNPs appear to be co-inherited. We
selected one of these SNPs (rs17817449) for genotyping. The risk
allele frequency showed increased significance in obese diabetic
patients when compared with non-diabetic non-obese individuals.
There is significant association with the risk of obesity. The pres-
ence of FTO risk allele showed borderline significance with
increased BMI. No significant association could be demonstrated
with T2D. Thus This gene variant might affect T2D through its rela-
tion to obesity and BMI.
A study of Quebec individuals reported that rs17817449 was
significantly associated with BMI, weight and waist circumference
under an additive model, and in addition, influenced fasting insulin
and HOMA-IR [40]. Another study in Mexican women demon-
strated that the FTO rs17817449 TT genotype predisposes its carri-
ers to fat deposition in the thoracic and breast region. Individuals
carrying this genotype showed a gynoid phenotype in Mexican
women [41]. Consistent with our findings Frayling et al. indicated
that the diabetes risk associated with the FTO locus is mediated by
obesity [42].4.8. MTHDF1
MTHFD1 is a key gene associated with three sequential enzy-
matic reactions in folic acid metabolism. Huang et al. stated that
subjects with the genotype AA of the MTHFD1 variant
(rs2236225) had a significantly lower susceptibility to T2D com-
pared with subjects with the GG or GG + GA genotypes [43]. In
the present work the MTHFD1 risk allele was significantly associ-
ated with obesity risk but not with T2D. Also the frequency of
the GA genotype was significantly increased in obese diabetic
patients when compared with non-obese non-diabetic individuals.
The risk allele was significantly associated with increased BMI.
These findings demonstrated the impact of MTHFD1 gene variant
on obesity risk with possible secondary impact on T2D.4.9. CDKN2A/B
In the current study significant association was found between
the risky TT genotype and T2D patients and highly significant asso-
ciation in obese-diabetic patients. A meta-analysis by Li et al. indi-
cated significant association between rs10811661 polymorphism
upstream of CDKN2A/B and T2D [44]. Consistent observations have
been detected in Japanese and Vietnamese population studies
[45,46]. Conversely in Czech Slavonic population study the associ-
ation between rs10811661 SNP and susceptibility to T2D was not
confirmed [47].
5. Conclusion
The inflammatory pathogenic mechanism and obesity are
major factors underlying the risk of T2D. Overlapping genetic
aspects should be considered and the presence of risk alleles of dif-
ferent genes together could contribute to the risk of T2D or obesity
or both. The MTHFD1 and EXT2rs3740878 gene variants signifi-
cantly affect obesity and not shared with T2D. Gene variants that
showed combined effect on both disease entities were GCKR and
PTGS1. These preliminary findings provide a basis for future studies
on a larger scale. More stress on the risk gene variants that have a
combined impact on both diabetes and obesity is recommended to
improve risk prediction and preventive strategies.
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